Compare Recursion Pharmaceuticals Inc (RXRX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $2.93 (market cap $1.53B), while Financial Select Sector SPDR Fund trades at $55.95. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLF | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | — |
52-Week High | $6.79 | $56.75 |
52-Week Low | $2.84 | $47.80 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
XLF trades at $56.04, down 0.39% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF benefits from strong bank earnings and dividend increases following Fed stress tests. Recent news highlights regional bank strength and AI-driven capital markets activity as key growth drivers.
Outlook remains positive due to robust financial sector performance and potential Fed rate hikes, though geopolitical risks and overbought conditions pose near-term headwinds. The ETF offers exposure to banking sector resilience with a low expense ratio of 0.08%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
